Fonterra is selling its China farms for a total of $NZ555 million, after successfully developing the farms alongside local partners.
Inner Mongolia Natural Dairy Company, a subsidiary of China Youran Dairy Group Limited, has agreed to buy Fonterra's two farming-hubs in Ying and Yutian for $NZ513 million.
Separately, Fonterra has agreed to sell its 85 per cent interest in its Hangu farm to Beijing Sanyuan Venture Capital Company, for $NZ42 million.
Sanyuan has a 15 per cent minority shareholding in the farm and exercised its right of first refusal to buy Fonterra's interest.
Related reading:
CEO Miles Hurrell said in building the farms, Fonterra had demonstrated its commitment to the development of the Chinese dairy industry.
"We've worked closely with local players, sharing our expertise in farming techniques and animal husbandry, and contributed to the growth of the industry," he said.
"We don't shy away from the fact that establishing farms from scratch in China has been challenging, but our team has successfully developed productive model farms, supplying high quality fresh milk to the local consumer market.
"It's now time to pass the baton to Youran and Sanyuan to continue the development of these farms."
Mr Hurrell said the sale of the farms would allow the co-op to prioritise the areas of its business where it had competitive advantages.
"For the last 18 months, we have been reviewing every part of the business to ensure our assets and investments meet the needs of the co-op today," he said.
"Selling the farms is in line with our decision to focus on our New Zealand farmers' milk.
"China remains one of Fonterra's most important strategic markets, receiving around a quarter of our production.
"Selling the farms will allow us to focus even more on strengthening our foodservice, consumer brands and ingredients businesses in China.
"We will do this by bringing the goodness of New Zealand milk to Chinese customers in innovative ways and continuing to partner with local Chinese companies to do so.
"Our investment in R&D and application centres in China will support this direction."
Completion of the sale, which is subject to anti-trust clearance and other regulatory approvals in China, is expected to occur within this financial year.
Want to read more stories like this?
Sign up below to receive our e-newsletter delivered fresh to your email in-box twice a week.